Your email has been successfully added to our mailing list.

×
0.0109119251753703 0.0109119251753703 0.00545596258768513 0.00545596258768513 -0.0693686671862821 -0.116999220576773 -0.0802026500389712 -0.0662509742790335
Stock impact report

Urovant Sciences Announces Publication of Results from Phase 1 Clinical Trials Evaluating URO-902 Gene Therapy in Patients with Overactive Bladder

UROVANT SCIENCES LTD COMMON (UROV) 
Last urovant sciences ltd common earnings: 2/13 04:15 pm Check Earnings Report
Company Research Source: Business Wire
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences (Nasdaq: UROV) announced today the publication of the safety and efficacy results of URO-902 in female patients with overactive bladder (OAB) from two double-blind, placebo-controlled randomized Phase 1 trials. The first trial was conducted with instillation therapy and the second trial with direct injections into the bladder wall under local anesthesia. The peer-reviewed publication was published online in Neurology and Urodynamics. URO-902, a naked DNA plasmid-based gene therapy administered via injection directly into the bladder, is currently being evaluated as a potential treatment for OAB in an ongoing Phase 2a study in the United States. In the trials, URO-902 was well tolerated and the administration via direct injection procedure demonstrated statistically significant improvement in OAB symptoms.“This is the first publication of clinical data for a potential novel gene therapy delivered directly to the Show less Read more
Impact Snapshot
Event Time:
UROV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for UROV alerts
Opt-in for
UROV alerts

from News Quantified
Opt-in for
UROV alerts

from News Quantified